Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
1 OBJECTIVES The purpose of this study is to evaluate the feasibility and acceptability of Waning Moon to inform future clinical trials. Our objectives are to 1) engage AI/AN partners to further co-develop the intervention protocols and training processes for licensed or prescribing providers 2) assess the feasibility and acceptability of Waning Moon. The data gathered will inform a future multisite efficacy study of the intervention. This work is supported by preliminary data from our co-development of Waning Moon.
1.1 Overall Study Methods This R34 will support a three-year project (Figure 4) to establish new relationships with AI/AN communities while strengthening our established 3-year relationship with Urban Indian Center of Salt Lake City (Letter of Support) and feasibility testing the Waning Moon intervention. Once all approvals are in place, we will develop a Leadership Advisory Board (LAB) comprised of UICSL clinical and community AI/AN leaders or members of the Utah Indian Health Advisory Board (UIHAB, Letter of Support); to recruit additional Community Advisory Board (CAB) members. Several prior CAB members wish to continue their engagement (Letter of Support). Should Waning Moon be deemed feasible and acceptable in the presently proposed study, the research team in collaboration with the Boards will design a subsequent multisite feasibility study in alignment with the NCCIH Research Framework.2
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前：Lisa J Associate Professor, College of Nursing, University of Utah
- 電話番号：801-585-5486
- メール：lisa.taylor-swanson@nurs.utah.edu
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Self-identifies as American Indian or Alaska Native
- Female, age 35-65
- Experiencing menopause-related symptoms (e.g., vasomotor symptoms)
- Able to attend sessions at Urban Indian Center of Salt Lake in Salt Lake City, Utah
- English-speaking
Exclusion Criteria:
- Currently enrolled in another menopause intervention study
- Does not identify as American Indian or Alaska Native
- Not experiencing menopause
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：Waning Moon Intervention
Four-session integrative medical group visit program delivered by community health workers with prescribing provider involvement.
Sessions cover menopause education, complementary health approaches including acupressure, mindfulness, and herbal supplements, and facilitated community discussion.
Participants also complete a follow-up visit at 12 weeks.
|
Waning Moon is a culturally tailored integrative medical group visit program developed by and for urban American Indian/Alaska Native women experiencing menopause.
The program consists of four weekly 90-minute group sessions delivered by trained licensed and/or prescribing providers, with involvement from prescribing providers.
Sessions integrate conventional and complementary menopause education, experiential practices (mindfulness, self-acupressure), and facilitated group discussion.
Topics include vasomotor symptoms, insomnia, stress, pain, inflammation, cardiovascular health, and goal setting.
Participants are referred to onsite prescribing providers for clinical evaluation and management as indicated.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility - Feasibility of Intervention Measure (FIM) scale
時間枠：Baseline (Week 0), post-intervention (Week 4), and 2-month follow-up (Week 12)
|
Participant-reported feasibility of the Waning Moon intervention as measured by the Feasibility of Intervention Measure (FIM) scale.
|
Baseline (Week 0), post-intervention (Week 4), and 2-month follow-up (Week 12)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intervention Appropriateness Measure (IAM)
時間枠：Baseline (Week 0), post-intervention (Week 4), and 2-month follow-up (Week 12)
|
Participant-reported acceptability of the Waning Moon intervention as measured by the Intervention Appropriateness Measure (IAM) scale.
|
Baseline (Week 0), post-intervention (Week 4), and 2-month follow-up (Week 12)
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intervention Fidelity
時間枠：Each Waning Moon session (Weeks 1 through 4)
|
Counts and proportions of fidelity to Waning Moon session manuals as measured by a fidelity checklist completed by the study team.
|
Each Waning Moon session (Weeks 1 through 4)
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 1R34AT013448-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Plan Description:
De-identified individual participant data will be archived in The Hive, a University of Utah research data repository maintained by the Marriott Library. Data will be shared no later than the time of publication or the end of the project period, whichever occurs first, and will remain available in the repository permanently. Each dataset will receive a Digital Object Identifier (DOI) to link the data to resulting publications. All data will be stripped of identifiers prior to sharing, consistent with participant consent and University of Utah and NIH data sharing policies.
Access Criteria:
De-identified data will be made publicly available in The Hive under a Creative Commons Attribution-NonCommercial license (CC BY-NC 4.0), which permits use with attribution to the data creators and prohibits commercial use. Data elements determined to carry a risk of indirect or deductive identification (e.g., geospatial indicators below the state level) will instead be provided as
IPD 共有時間枠
IPD 共有アクセス基準
Who: Any qualified researcher may access de-identified data made publicly available in the repository. Researchers seeking restricted-access data elements (those carrying a risk of indirect or deductive identification) must demonstrate a valid research need and agree to conditions of use under a data use contract.
What: De-identified individual participant data, along with the Study Protocol and Informed Consent Form, will be accessible. Data determined to carry re-identification risk (e.g., geospatial indicators below the state level) will be withheld from public access and offered only under restricted-access terms.
How: Data will be archived in The Hive, a University of Utah research data repository maintained by the Marriott Library, under a Creative Commons Attribution-NonCommercial license (CC BY-NC 4.0), which requires attribution to the data creators and prohibits commercial use. Each dataset will receive a Digital Object Identifier (DOI) linking it to resulting publications.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。